# **Baseline correlates of retention in HIV primary care at six HIV clinics in the U.S.**

# Results from the Control Arm of a CDC/HRSA Trial to Retain Patients in HIV Primary Care

#### **Jason Craw**

Public Health Analyst, ICF International

7<sup>th</sup> International Conference on HIV Treatment and Prevention Adherence: June 4, 2012

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of HIV/AIDS Prevention

# **Co-authors**

- Tracey E. Wilson<sup>1</sup>
- **Thomas Giordano<sup>2</sup>**
- Michael Mugavero<sup>3</sup>
- Jeanne Keruly<sup>4</sup>
- Mari-Lynn Drainoni<sup>5</sup>
- Allan Rodriguez<sup>6</sup>
- Robert Mills<sup>7</sup>
- Lytt Gardner<sup>8</sup>

School of Public Health, SUNY Downstate Medical Center
Baylor College of Medicine, Thomas Street Health Center, & DeBakey VA Medical Center
University of Alabama at Birmingham, UAB Center for AIDS Research, & UAB 1917 Clinic
Johns Hopkins University, Department of Medicine
Boston University School of Public Health, Boston University School of Medicine, & CHQOER, ENRM VA Hospital
University of Miami Miller School of Medicine
HIV/AIDS Bureau, Health Resources and Services Administration
Centers for Disease Control and Prevention, NCHHSTP/DHAP/Epi

# **Retention in Care Study Design & Intervention**

## Study Design

- 3-arm randomized trial evaluating retention in HIV primary care
- 6 HIV clinics in the U.S. (minimum 1,000 patients)
- 12-month intervention delivery period
- 12 months post-intervention to monitor primary care attendance

## Study Trial Arms

- Intervention Arm 1: HIV education + "enhanced contact"
- Intervention Arm 2: HIV education + "enhanced contact" + skill modules (organization, problem-solving, communication)
- Control Arm: clinical standard of care\*\*\*

\*\*\* Today's presentation will address retention outcomes in the control arm from the first 12 months of the study

# **Study Enrollment Criteria**

Prior Primary Care Visit History (must meet one of the following to be eligible):


- 1+ missed (no-show) visits in the 12 months prior to enrollment
- Failed to have ≥1 arrived primary care visit in each 6-month period in 12 months prior to enrollment
- "New" patients (new to HIV care or new patient at clinic)

#### Other Enrollment Criteria:

- HIV-positive patients receiving primary care at the clinic
- 18 years of age or older at time of enrollment
- Able to speak English or Spanish

# **Clinic study site locations**

#### A Baltimore, Birmingham, Boston, Brooklyn, Houston, & Miami




# **Defining Retention in Care Measures**

# Visit Constancy (visit per interval)

- Measures regularity/consistency of being seen for care
- 4-month visit constancy: ≥1 primary care visit in each of three consecutive 4-month intervals in 12-mo. period
- Analyzed as dichotomous 0/1 outcome (no/yes)

# Multiple Missed Visits (2 or more missed visits)

- Measures appointment-keeping behavior
- Defined as 2+ missed (no-show) visits in 12-mo. period
- Analyzed as dichotomous 0/1 outcome (no/yes)



Adapted from slide courtesy of Dr. Michael Mugavero (UAB)

## **Independent Variables Investigated**

- Demographic: age, sex, race, patient type (new vs. established), insurance, housing
- Behavioral: HIV risk factor, recent drug and alcohol use (past 3 mo.), recent incarceration (past 6 mo.)
- Unmet needs (e.g., substance abuse tx, food/groceries, housing, employment assistance, benefits, etc.)
  - "Unmet needs" any service the patient needed in the past 6 months that s/he was unable to obtain
- **Barriers to care (paying for HIV care, transportation)**
- Clinical variables: baseline CD4/VL\*, on ART at baseline

\* Baseline CD4, baseline viral load test window: ±100 days around enrollment date

# Methods

- Calculated two different retention in care outcomes among 611 control arm trial participants.
- Collected baseline self-reported patient data from a computer survey.
- Baseline clinical data abstracted from medical records.
- Chi square, t-tests (bivariate)
- Multivariate analysis (log-binomial regression) to estimate prevalence ratios

# BASELINE CHARACTERISTICS OF CONTROL ARM PARTICIPANTS

# **Baseline Demographics (N=611)**

Demographics	Ν	Percent
Patient Type		
New Patients	172	28.2
Established Patients	439	71.8
Sex		
Males	379	62.0
Females	227	37.2
Transgender	5	0.8
Race/ethnicity		
Black/African American	408	66.8
Hispanic/Latino	108	17.7
White	75	12.3
Other (Asian, NH/PI, Al/AN, multi-race)	20	3.3
Age at time of enrollment	609	<u>Mean (median), range</u>
		44.1 (45), 20-75
Age, categorical		
18-29	73	12.0
30-39	122	20.0
40-49	211	34.7
50+	203	33.3

# **Baseline Demographics (2)**

Demographics	N	Percent
HIV Risk Factor		
MSM	152	24.9
MSM+IDU	15	2.5
IDU	95	15.6
Heterosexual	299	48.9
Other (e.g., perinatal,	50	8.2
blood transfusion, unknown risk factor)		
Housing		
Own home/apartment	381	62.5
Someone else's home/apartment	154	25.2
Supported/transitional housing	30	4.9
Other (inc. homeless/no place to stay)	45	7.4
Primary Insurance		
Private	91	14.9
Medicare	129	21.1
Medicaid	232	38.0
Uninsured (includes Ryan White)	139	22.7
None	20	3.3

# Baseline Behavioral Variables and Barriers to Care/Unmet Needs

Behavioral	Ν	Percent
ANY drug use, past 3 months	114	18.7
Binge drinking, past 3 months	121	19.8
Incarcerated, past 6 months	61	10.0

Barriers to care/unmet needs	Ν	Percent
Any unmet needs, past 6 months	237	38.8
Barrier to care: worried about how to pay for HIV medical care	158	25.9
Barrier to care: transportation	110	18.1

# **Baseline Clinical Variables**

Clinical	Ν	Percent
Baseline ART (on ART meds?)		
Self-report (ACASI)*	461	75.6
Medical records	472	77.2
Baseline undetectable VL		
<200 copies/mL	339	55.5
Baseline CD4+ T-lymphocyte count		
<200 cells/mL	106	18.4
200-349 cells/mL	125	21.7
≥350 cells/mL	346	60.0
Mean (Median), IQR		Mean (Median), IQR
	577	456 (408), 258-619

\* 88% agreement between self-report and medical record review for being on ART at baseline

# **RETENTION OUTCOME RESULTS FOR CONTROL ARM PARTICIPANTS**

# Summary of 4-mo. Visit Constancy & Missed Visits in Control Arm Participants (n=611)

Primary care visit attendance in 12-mo. period after enrolling in the study	Ν	Percent
Did not meet 4-month visit constancy	331	54.2%
2 or more missed visits	265	43.4%

Relationship between the two retention measures:
4-month visit constancy and 2 or more missed visits

Modest association (Φ coefficient: -0.19)

## Baseline Demographic Correlates:\* 4-month Visit Constancy and 2+ Missed Visits

	Ν	Number (%) <u>failing</u> to meet 4-month visit constancy	p-value	Number (%) w/ 2+ missed visits	p-value
<mark>Gender</mark> Male Female	379 227	215 (56.7%) 112 (49.3%)	0.08	151 (39.8%) 110 (48.5%)	0.04
Race Black Hispanic White Other	408 108 75 20	225 (55.1%) 51 (47.2%) 42 (56.0%) 13 (65.0%)	0.35	194 (47.6%) 40 (37.0%) 23 (30.7%) 8 (40.0%)	0.02
Age 18-29 30-39 40-49 50+	73 122 211 203	40 (54.8%) 72 (59.0%) 111 (52.6%) 107 (52.7%)	0.67	41 (56.2%) 63 (51.6%) 85 (40.3%) 75 (36.9%)	0.0059

\* Unadjusted results

### Baseline Demographic Correlates (2):\* 4-month Visit Constancy and 2+ Missed Visits

	Ν	Number (%) <u>failing</u> to meet 4-month visit constancy	p-value	Number (%) w/ 2+ missed visits	p-value
Primary Insurance					
Private	91	40 (44.0%)	0.0023	26 (28.6%)	0.02
Medicare	129	72 (55.8%)		<b>59 (45.7%)</b>	
Medicaid	232	<b>116 (50.0%)</b>		113 (48.7%)	
Uninsured/None	139	<b>86 (61.9%)</b>		58 (41.7%)	
Housing					
Own home/apt	381	200 (52.5%)	0.07	<b>162 (42.5%)</b>	0.53
Other's home/apt	154	<b>92 (59.7%)</b>		74 (48.0%)	
Transitional housing	30	11 ( <b>36.7</b> %)		12 (40.0%)	
Other	45	28 (62.2%)		17 (37.8%)	

\* Unadjusted results

## Baseline Clinical Correlates:\* 4-month Visit Constancy and 2+ Missed Visits

	N	Number (%) <u>failing</u> to meet 4-month visit constancy	p-value	Number (%) 2+ missed visits	p-value
Baseline ART Yes No	472 139	251 (53.2%) 80 (57.5%)	0.36	191 (40.5%) 74 (53.2%)	0.0076
Baseline viral load <200 copies/mL ≥200 copies/mL	339 272	167 (49.3%) 164 (60.3%)	0.0065	113 (33.3%) 152 (55.9%)	<0.0001
Baseline CD4 count <350 cells/mL ≥350 cells/mL	231 346	131 (56.7%) 174 (50.3%)	0.13	120 (52.0%) 130 (37.6%)	0.0006

\* Unadjusted results

# Other demographic, behavioral, and unmet need/barrier to care correlates

## The following variables were not associated with 2+ missed visits or 4-month visit constancy:

- Patient type (new vs. established patients)
- HIV risk factor
- Any drug use, past 3 months
- Binge drinking, past 3 months
- Incarceration, past 6 months
- Any unmet needs, past 6 months
- Barriers to care (transportation, payment for HIV medical care)

# **Multivariate Results:\* 2 or more missed visits**

	Prevalence Ratio (95% CI)	p-value
Gender: Females vs. Males	1.01 (0.85, 1.20)	0.90
Race: Black vs. White	1.22 (0.94, 1.59)	0.14
Race: Hispanic vs. White	1.06 (0.76 <i>,</i> 1.48)	0.74
Age: 18-29 vs. 50+	1.35 (1.05, 1.75)	0.02
Age: 30-39 vs. 50+	1.26 (1.01, 1.58)	0.04
Age: 40-49 vs. 50+	1.06 (0.87, 1.29)	0.60
Insurance: Medicare vs. Private	1.42 (1.07, 1.90)	0.01
Insurance: Medicaid vs. Private	1.36 (1.04, 1.77)	0.02
Insurance: None/Uninsured vs. Private	1.26 (0.94, 1.69)	0.13
Baseline VL: ≥200 vs. <200 copies/mL	1.43 (1.18, 1.73)	0.0002
Baseline CD4 cell count: <350 vs.≥350	1.08 (0.91, 1.27)	0.40
Baseline ART: yes vs.no	1.04 (0.85, 1.28)	0.70

\* Also adjusted for study site

# Multivariate Results:\* failed 4-mo visit constancy

	Prevalence Ratio (95% CI)	p-value
Gender: Males vs. Females	1.08 (0.96, 1.21)	0.20
Race: Black vs. White	1.05 (0.90, 1.23)	0.56
Race: Hispanic vs. White	0.93 (0.76, 1.13)	0.47
Age: 18-29 vs. 50+	1.03 (0.86, 1.22)	0.76
Age: 30-39 vs. 50+	1.07 (0.93, 1.24)	0.36
Age: 40-49 vs. 50+	1.00 (0.88, 1.13)	0.97
Insurance: Medicare vs. Private	1.13 (0.94, 1.35)	0.19
Insurance: Medicaid vs. Private	1.09 (0.92, 1.29)	0.31
Insurance: None/Uninsured vs. Private	1.11 (0.94, 1.32)	0.22
Housing: other's home vs. own home	1.00 (0.89, 1.12)	0.95
Transitional housing vs. own home	0.82 (0.62, 1.07)	0.14
Baseline VL: ≥200 vs. <200 copies/mL	1.05 (0.95, 1.17)	0.34
Baseline CD4 cell count: <350 vs.≥350	1.02 (0.92, 1.14)	0.71

\* Also adjusted for study site

# Conclusions

- Visit constancy (regularity of care) and missed visits (appointment keeping) capture two important yet conceptually different measures of retention in care.
- We found consistent patterns of association (e.g., age, insurance, baseline viral load) and inconsistent patterns of association (e.g., gender, race) across these two retention outcome measures.
- Younger age (18-29, 30-39), non-private insurance (Medicare, Medicaid), and having a detectable baseline viral load were associated with having 2+ missed visits in multivariate model.
- We were unable to confirm correlates reported previously in the retention literature (e.g., recent drug/alcohol use, unmet needs, barriers to care) in the control arm of our study.

## Acknowledgements

#### U. of Alabama-Birmingham

Michael Mugavero Michael Saag Scott Batey Anne Zinski Stephanie Gaskin Jill Murphree Jim Raper James Willig Suneetha Thogaripally

#### Baylor College of Medicine-Thomas Street Health Ctr, Houston, TX

Tom Giordano Jessica Davila Hina Budhwani Tawanna Biggs Shapelle Payne Nancy Miertschin David Bartholomew Monisha Arya William Slaughter Christine Jacobsen

#### Boston University Medical

<u>Center</u> Mari-Lynn Drainoni Meg Sullivan Jon Hall Maya McDoom Michal Naisteter Karina Osella Cintia Ferreira Lisa Koppelman Mary Gaeddert

#### Johns Hopkins University

Richard Moore Jeanne Keruly Mollie Jenckes Melissa Otterbein Angie McCray Mary McGann Liming Zhou

#### Mountain Plains AETC

Lucy Bradley-Springer Marla Corwin

#### SUNY Downstate Medical Ctr, Brooklyn, NY

Tracey Wilson Susan Holman Mayange Frederick Harry Johnson Elana Desrivieres Sophia Gibbs-Cohen Tonya Taylor Kevin Gravesande

#### University of Miami (FL)

Allan Rodriguez Lisa Metsch Kathy Mercogliano Carolyn Garzon Marvin Shika Jesline Jean-Simon Gilbert Saint-Jean

#### **Federal**

Laura Cheever, HRSA Faye Malitz, HRSA Robert Mills, HRSA Lytt Gardner, CDC Gary Marks, CDC Jason Craw, CDC/ICF Sonali Girde, CDC/ICF

### **Additional Presentations: Retention in Care Study**

- "Measuring Retention in HIV Care: The Elusive Gold Standard" (Dr. Mugavero) today at 4:00p in Ocean Tower 2 Ballroom.
- "CDC/HRSA Multisite Retention in Care Study: Preliminary Results" (Dr. Gardner, Dr. Marks) Tuesday at 2:15p in Ocean Tower 1C.

## **Contact Information**

For more information please contact: Jason Craw, MPH JCraw@cdc.gov or Jason.Craw@icfi.com (404) 639-6395

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



National Center for HIV/AIDS, Viral Hepatitis, STD , and TB Prevention Division of HIV/AIDS Prevention (DHAP)